Voyager Therapeutics, Inc. (VYGR)
- Previous Close
7.57 - Open
7.60 - Bid 7.62 x 100
- Ask 7.66 x 100
- Day's Range
7.57 - 7.78 - 52 Week Range
6.06 - 14.34 - Volume
366,047 - Avg. Volume
641,541 - Market Cap (intraday)
415.4M - Beta (5Y Monthly) 0.95
- PE Ratio (TTM)
2.58 - EPS (TTM)
2.97 - Earnings Date May 7, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
17.78
Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
www.voyagertherapeutics.comRecent News: VYGR
Performance Overview: VYGR
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VYGR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VYGR
Valuation Measures
Market Cap
414.86M
Enterprise Value
204.27M
Trailing P/E
2.57
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.36
Price/Book (mrq)
1.76
Enterprise Value/Revenue
0.82
Enterprise Value/EBITDA
1.62
Financial Highlights
Profitability and Income Statement
Profit Margin
52.93%
Return on Assets (ttm)
29.87%
Return on Equity (ttm)
89.61%
Revenue (ttm)
250.01M
Net Income Avi to Common (ttm)
132.33M
Diluted EPS (ttm)
2.97
Balance Sheet and Cash Flow
Total Cash (mrq)
230.88M
Total Debt/Equity (mrq)
8.59%
Levered Free Cash Flow (ttm)
-3.01M
Research Analysis: VYGR
Company Insights: VYGR
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: VYGR
Daily – Vickers Top Buyers & Sellers for 10/06/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 02/02/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 01/27/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.